Tina Hesman Saey

Tina Hesman Saey

Senior Writer, Molecular Biology

Senior writer Tina Hesman Saey is a geneticist-turned-science writer who covers all things microscopic and a few too big to be viewed under a microscope. She is an honors graduate of the University of Nebraska-Lincoln where she did research on tobacco plants and ethanol-producing bacteria. She spent a year as a Fulbright scholar at the Georg-August University in Göttingen, Germany, studying microbiology and traveling.  Her work on how yeast turn on and off one gene earned her a Ph.D. in molecular genetics at Washington University in St. Louis. Tina then rounded out her degree collection with a master’s in science journalism from Boston University. She interned at the Dallas Morning News and Science News before returning to St. Louis to cover biotechnology, genetics and medical science for the St. Louis Post-Dispatch. After a seven year stint as a newspaper reporter, she returned to Science News. Her work has been honored by the Endocrine Society, the Genetics Society of America and by journalism organizations.

All Stories by Tina Hesman Saey

  1. APOE protein model
    Genetics

    Genetic risk factors for Alzheimer’s also raise the risk of getting COVID-19

    People who have the APOE4 genetic variant appear to be more vulnerable to the disease, but it’s unclear why.

  2. Hydroxychloroquine bottles
    Health & Medicine

    Politics aside, hydroxychloroquine could (maybe) help fight COVID-19

    Hydroxychloroquine may help prevent COVID-19, or it may not. Studies are under way to find out. Meanwhile, here’s what we know.

  3. Two versions of the coronavirus SARS-CoV-2
    Health & Medicine

    There are two versions of the coronavirus. One’s not more dangerous than the other

    Factors such as a person’s age and white blood cell counts matter more for disease severity when it comes to COVID-19, a study finds.

  4. woman working in a lab
    Health & Medicine

    As we wait for a vaccine, here’s a snapshot of potential COVID-19 treatments

    Though a vaccine remains the ultimate goal, researchers are on the hunt for new ways to treat COVID-19.

  5. Experimental vaccine injection
    Health & Medicine

    Moderna’s COVID-19 vaccine stimulates an immune response in people

    An mRNA vaccine triggers the immune system to make as many virus-blocking antibodies as in people who have recovered from COVID-19, early data show.

  6. Peruvian man walking up cobblestone path
    Humans

    A gene variant partly explains why Peruvians are among the world’s shortest people

    A gene variant reduces some Peruvians’ height by about 2 centimeters, on average, the biggest effect on stature found for a common variation in DNA.

  7. Remdesivir production
    Health & Medicine

    The new COVID-19 drug remdesivir is here. Now what?

    Remdesivir may shorten recovery time for some people, but it isn’t available to everyone and it won’t end the pandemic on its own.

  8. Coronavirus electron micrograph image
    Health & Medicine

    Loss of smell and taste may actually be one of the clearest signs of COVID-19

    Data from a symptom tracker smartphone app used by millions of people shows two-thirds of positive patients reported losing these senses.

  9. COVID-19 patient in Hong Kong
    Health & Medicine

    A multiple sclerosis drug may speed COVID-19 recovery

    One form of interferon may boost the immune system’s ability to fight the coronavirus early in infections, a small study suggests.

  10. Health & Medicine

    Some existing drugs might fight COVID-19. One may make it worse

    Maps of interactions between coronavirus proteins and host proteins point to drugs that may slow viral growth, but cough medicine may stimulate growth.

  11. Remdesivir
    Health & Medicine

    Remdesivir is the first drug found to block the coronavirus

    Preliminary results suggest that an antiviral treatment speeds recovery from COVID-19.

  12. Malaria drug hydroxychloroquine
    Health & Medicine

    More evidence hints that hydroxychloroquine doesn’t help treat COVID-19

    A malaria drug showed no benefit over standard care in two preliminary studies examining how well hydroxychloroquine works against the coronavirus.